BLA 022472 · Mannkind
Afrezza
Insulin Recombinant Human · Inhalation · Insulin
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jun 27, 2014
Approved uses
4
Original approval plus efficacy supplements
Registered trials
100
15 Phase 3, 0 recruiting
FAERS reports
8,026
5,651 serious, 789 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD) [see Warnings and Precautions ( 5.1 )]. AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD [see Contraindications ( 4 )]. Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV 1 ) to identify potential lung disease in all patients [see Dosage and Administration ( 2.1 ), Warnings and Precautions ( 5.1 )]. WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE See full prescribing information for complete boxed warning. Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD). ( 5.1 ) AFREZZA is contraindicated in...
What it is approved for
From the label in effect May 30, 2026.
AFREZZA ® is indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus. AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for the treatment of diabetic ketoacidosis (DKA) ( 1 ) Not recommended in patients who smoke or who have recently stopped smoking ( 1 ) Limitations of Use: AFREZZA is not recommended for the treatment of diabetic ketoacidosis (DKA) [see Warnings and Precautions ( 5.6 )] . The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking [see Warnings and Precautions ( 5.5 )].
Mechanism: Insulin lowers blood glucose levels in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 2026 Supplement 29 · Efficacy LabelMedication GuideLetter
- Jan 23, 2026 Supplement 27 · Efficacy LetterLetterLabel
- Sep 29, 2017 Supplement 11 · Efficacy LetterLabel
- Jun 27, 2014 Original approval · Type 5 - New Formulation or New Manufacturer LabelSummary ReviewReview
3 products under this application
- AFREZZA · INSULIN RECOMBINANT HUMAN 12 UNITS/INH · POWDER, INHALATION · Prescription
- AFREZZA · INSULIN RECOMBINANT HUMAN 4 UNITS/INH · POWDER, INHALATION · Prescription
- AFREZZA · INSULIN RECOMBINANT HUMAN 8 UNITS/INH · POWDER, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Recombinant Human" as an intervention, any sponsor and status, largest first.
- The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)Pivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00004984 · 711 participants · Start Feb 1994 · Primary completion Jun 2003
Drug: Parenteral Insulin; Oral Insulin and 1 more · For: Diabetes Mellitus, Type 1
Sites: Los Angeles, California; San Francisco, California; Stanford, California · 15 sites in all
- Assessment of Mechanisms of Improved Wound HealingPivotal-lookingCompleted
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00673309 · 644 participants · Start Jul 2000 · Primary completion Apr 2011
Drug: Insulin High Dose; oxandrolone and 8 more · For: Burns
Sites: Galveston, Texas
- Combination of Corticotherapy and Intensive Insulin Therapy for Septic ShockPivotal-lookingCompleted
University of VersaillesAcademic, hospital or other
NCT00320099 · 508 participants · Start Jan 2006 · Primary completion Jan 2009
Drug: recombinant human insulin; hydrocortisone and 2 more · For: Septic Shock
Sites: Bobigny, France; Bondy, France; Grenoble, France · 8 sites in all
- CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)Pivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01848990 · 456 participants · Start Mar 2013 · Primary completion Feb 2014
Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Precommercial Hylenex recombinant (hyaluronidase human injection) and 3 more · For: Type 1 Diabetes Mellitus
Sites: Concord, California; Encino, California; Escondido, California · 39 sites in all
- Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic PatientsPivotal-lookingCompleted
Sun Yat-sen UniversityAcademic, hospital or other
NCT01147627 · 416 participants · Start Aug 2010 · Primary completion Aug 2012
Drug: exenatide injection; Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R and 1 more · For: Diabetes Mellitus, Type 2; Newly Diagnosed
Sites: Beijing, China; Guangzhou, China; Qingyuan, China · 25 sites in all
- A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 DiabetesPivotal-lookingTerminated
Diamyd Medical ABIndustry
NCT05018585 · 321 participants · Start May 19, 2022 · Primary completion Jun 24, 2026
Drug: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®; Placebo · For: Type 1 Diabetes Mellitus
Sites: Newport Beach, California; Palo Alto, California; San Diego, California · 60 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00642941 · 317 participants · Start Dec 18, 2007 · Primary completion Feb 19, 2014
Drug: RG1507 · For: Sarcoma
Sites: Duarte, California; Los Angeles, California; Santa Monica, California · 41 sites in all
- The Effect of Intensive Insulin Therapy in the Surgical Critical Care UnitPivotal-lookingCompleted
GenesysAcademic, hospital or other
NCT00282594 · 317 participants · Start Jul 2003
Drug: Novolin R (human recombinant Insulin) · For: Sepsis; Respiratory Failure; Renal Failure and 1 more
Sites: Grand Blanc, Michigan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased1,327
- drug ineffective583
- hypoglycaemia458
- cough446
- blood glucose decreased398
- dyspnoea398
- hyperglycaemia357
- diarrhoea341
- off label use319
- headache283
- nausea271
- wrong technique in product usage process263
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 54 |
| 2005 | 54 |
| 2006 | 44 |
| 2007 | 73 |
| 2008 | 69 |
| 2009 | 67 |
| 2010 | 76 |
| 2011 | 100 |
| 2012 | 96 |
| 2013 | 160 |
| 2014 | 369 |
| 2015 | 1,116 |
| 2016 | 315 |
| 2017 | 201 |
| 2018 | 512 |
| 2019 | 448 |
| 2020 | 400 |
| 2021 | 581 |
| 2022 | 791 |
| 2023 | 701 |
| 2024 | 681 |
| 2025 | 647 |
| 2026 | 471 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Afrezza (Insulin Regular, Human)
2024 spending
$26.9M
Beneficiaries
3,114
13,165 claims
Per beneficiary
$8,632
$8.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,007,830 |
| 2021 | $10,393,693 |
| 2022 | $12,896,498 |
| 2023 | $22,608,794 |
| 2024 | $26,879,300 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Afrezza on Glucose Dynamics During HCL Treatment.
Galderisi A, Cohen N, Calhoun P, et al. · Diabetes Care 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera.
Al-Tabakha MM · J Control Release 2015 · Systematic Review
- Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes: The INHALE-3 Extension Study.
Beck RW, Bailey RJ, Klein KR, et al. · Diabetes Technol Ther 2025 · Randomized Controlled Trial, Multicenter Study
- A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes.
Beck RW, Bailey RJ, Akturk HK, et al. · Diabetes Technol Ther 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Mannkind
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.